Health
Nigeria to Begin Malaria Vaccine Trials in Six Weeks—NAFDAC DG
By Adedapo Adesanya
The Director General of the National Agency For Food and Drug Administration and Control (NAFDAC), Mrs Mojisola Adeyeye, has said the approval process for the R21/Matrix-M malaria vaccine requires more clinical trials before its full use.
She made this disclosure on Wednesday morning while speaking on Channels Television.
In her words, “The clinical trial will begin within the next six weeks. The RTS,S did not include Nigeria, because from the beginning the effectiveness was 30 per cent, so we did not agree to join the clinical trial.”
Mrs Adeyeye noted that development in a country’s governance is a contributing factor to the persistence of malaria in Africa.
She also stated that the provision of the vaccine is important for transmission prevention, adding that NAFDAC is going to do its own test, trials and levels of approval.
“For the R21, after reading the dossier, I believe Nigeria should join. This is because we have a high probability of success. If something is 75 per cent effective from the beginning, then we know they are very likely to be successful. It has 75 per cent effectiveness for a malaria vaccine, which is great.
Mrs Adeyeye noted that phase four clinical trials would be conducted and more laboratory work.
“However, it is not what is written only that we know as the efficacy; we have to check every line of the dossier to ensure that science speaks. This is science-driven. What we did was to have two sets of reviews,” she said.
According to her, for the first time in the agency’s history, NAFDAC is going to have an external expert body for phase four.
“We are going to do phase four clinical trials; it should be tested in our country. We are going to do more observation. This would involve more laboratory works, this cannot be administered until it goes through a testing process in the country before the transmission process,” Mrs Adeyeye disclosed.
The NAFDAC DG stated that the vaccination focus is mainly on children and not adults, adding that this was the limitation the RTS,S malaria vaccine had in its percentage efficacy.
“Even if it is only 30 per cent of the children that will not die or the death would be prevented, that will be good enough. But we didn’t take that up as an agency to be part of the trial. This particular R21 had been submitted to WHO, and they are going to be doing their own review,” she said.
“NAFDAC approved the R21 vaccine for children under five, specifically for those under three years. NAFDAC tested the second vaccine (RTSS), and it was not found effective enough. Nigeria is part of this one, that is R21; we gave provisional approval after a very rigorous approval process.”
In a related development, the world celebrated World Malaria Day yesterday (April 25) and the World Health Organisation (WHO) called on African leaders to increase their investment in health as part of efforts to rapidly reduce the burden of malaria and save the lives of its populations.
WHO Country Representative in Nigeria, Mr Walter Mulombo, made the appeal at a media roundtable to commemorate the 2023 World Malaria Day (WMD) in Abuja on Tuesday.
Mr Mulombo said malaria intervention, like any other health intervention,, should not be seen as a burden for the government or partners but as an enabling factor for social economic development.
By Modupe Gbadeyanka
Dr Obi Adigwe has been appointed as the pioneer National Coordinator of the National Health Technology and Data Analytics Office (NHTDAO).
The body was created by the Ministry of Health under the approval of President Bola Tinubu.
NHTDAO will be domiciled in the Office of the Coordinating Minister of Health and Social Welfare, a statement on Friday by the Special Adviser to the President on Information and Strategy, Mr Bayo Onanuga, stated.
The agency will serve as a meta-level national platform for coordinating the country’s digital-health agenda. It will reinforce, not replace, the existing statutory functions of relevant departments and agencies, it was emphasised.
The organisation will also harmonise and empower the public and private institutions across the health system, set the standards that connect them, and operationalise the National Digital Health Architecture, approved by the National Council on Health in November 2025.
It was stated that President Tinubu expects NHTDAO to accelerate Nigeria’s transition to a secure, interoperable and data-driven health system that improves outcomes for all citizens.
Mr Adigwe, as Director General of the National Institute for Pharmaceutical Research and Development, has leveraged science to catalyse interventions in artificial intelligence, translational research, and technology transfer.
He coordinated major projects, including the ¥300m Nanotechnology grant and the AFREXIMBank grant for Africa’s first API Training Facility. He led the roadmap development that underpinned an €18 million EU grant, the largest in Africa for the thematic area. During the last pandemic, Adigwe globally showcased African science by undertaking the world’s first analysis to debunk claims about the Covid Organics preparation.
The Office’s Steering Committee, which provides strategic direction and oversight, comprises:
- Professor Muhammad Ali Pate, Coordinating Minister of Health and Social Welfare (Co-chair)
- Mr Olaniyi Yusuf, Chairman of the Nigerian Economic Summit Group (Co-chair)
- Dr Iziaq Adekunle Salako, Minister of State for Health and Social Welfare (Alternate Co-chair)
- Ms Kachollom Daju, Permanent Secretary, Federal Ministry of Health and Social Welfare
- Mr Idris Alubankudi Saliu, Special Adviser to the President on Technology and Digital Economy
- Dr Muntaqa Umar-Sadiq, National Coordinator, SWAp Coordination Office
- Dr Abdu Mukhtar, National Coordinator, Presidential Initiative to Unlock Healthcare Value Chain
- Dr Muyi Aina, Executive Director, National Primary Health Care Development Agency
- Dr Kelechi Ohiri, Director General, National Health Insurance Authority
- Director, Health Planning, Research and Statistics, Ministry of Health and Social Welfare
- National Information Technology Development Agency Representative
- Six representatives of the State Commissioners of Health, one from each of the six geopolitical zones
- Pharm Hamza Buhari, Stakeholder representing Industry and Community.
By Modupe Gbadeyanka
The Lagos State government has kicked off an initiative to ensure that every newborn is screened for Sickle Cell Disease within 48 to 72 hours after birth using a simple heel-prick test.
It was gathered that babies identified as being at risk will immediately be placed on preventive care while awaiting confirmatory testing.
The Head of the Haematology Department at the Alimosho General Hospital, Dr Olubukola Orolu, revealed that an estimated 150,000 babies are born annually with Sickle Cell Disease in Nigeria, giving the country one of the highest SCD burdens globally.
She, however, applauded the Lagos State Government and the Clinton Health Access Initiative (CHAI) for introducing the state-wide newborn screening programme, describing it as a major step towards reducing childhood deaths associated with the disease.
The commencement of this scheme coincides with the 2026 World Sickle Cell Day, themed Young Voices Rising for Sickle Cell Disease – Closing the Survival Gap: Equity in Sickle Cell Disease.
It highlights the importance of listening to the experiences and aspirations of young people living with Sickle Cell Disease.
Mrs Orolu noted that SCD warriors are increasingly breaking barriers as advocates, leaders, students and change-makers, adding that their voices have continued to reshape the narrative through advocacy for equitable, patient-centred healthcare, self-care and experience sharing.
She, therefore, called for equal access to quality healthcare, survival opportunities and dignity for everyone living with Sickle Cell Disease.
Also commenting, the chief executive of Alimosho General Hospital, Dr Akinyele Akinlade, described Sickle Cell Disease as an inherited blood disorder that is not contagious, noting that individuals living with the condition are more susceptible to infections.
He advised SCD warriors to stay well hydrated, avoid stress, and protect themselves from extreme cold or heat, as these are common triggers of sickle cell crises, adding that these preventive measures can significantly reduce the frequency and severity of crises.
One of the participants, Ms Borokini Zainab, an SCD warrior and student nurse, expressed appreciation to the organisers for the enlightenment programme.
Sharing her personal journey, she spoke about the challenges of balancing recurrent pain crises with her academic pursuits and personal life. Despite moments of frustration, she encouraged fellow warriors not to lose hope.
“Don’t let sickle cell put you down. Be encouraged from within. Don’t let your dreams be shattered because of this,” she said, adding that her personal experience with Sickle Cell Disease inspired her to pursue a career in nursing so she could support others living with the condition.
By Aduragbemi Omiyale
A 12-week health-tech incubation programme tailored for early-stage founders in Nigeria has been introduced by an innovation and venture-building platform, Evon Labs.
This initiative, known as HealthX Catalyst, will help participants to create scalable, investable solutions for Africa’s urgent healthcare issues.
The programme is underway, with 12 selected founders nearing the final weeks of intensive incubation, ending with a Demo Day on June 24, 2026, at the UNDP innovation centre in Lagos, where the small business owners will present their solutions to an audience of investors, healthcare leaders, development organisations, and technology partners.
The initiative selects early-stage healthcare founders and immerses them in a structured 12-week development process. Throughout this period, participants receive personalised and group mentorship from seasoned professionals across the healthcare, technology, and business sectors.
They also receive structured support for startup development, including refining business models, developing value propositions, and validating markets.
Additionally, participants gain access to a network of healthcare practitioners, sector experts, and industry leaders, along with targeted investment-readiness assistance to prepare them to engage with investors and strategic partners after the programme.
The result is a cohort of founders who move through the programme not simply with a refined pitch, but with a validated business model, a stronger professional network, and a clear pathway to growth.
To accelerate the most promising solutions beyond the programme, monetary grants will be awarded to the top three founders to support product development, pilot implementation, market validation, and early-stage scaling.
It was learned that HealthX Catalyst was developed in response to a structural gap in the African health-tech ecosystem.
Across the continent, a growing number of entrepreneurs are building solutions to healthcare problems from access and diagnostics to service delivery and health data infrastructure. Yet many of these early-stage ideas fail to progress beyond concept, not for lack of vision, but for lack of structured support: mentorship, startup development frameworks, industry access, and early-stage funding pathways. HealthX Catalyst was built to provide exactly that.
“Africa does not have a shortage of healthcare innovators. What it has lacked is the infrastructure to turn its ideas into sustainable businesses. HealthX Catalyst is that infrastructure, a serious, structured programme designed to take founders from early-stage ideas to investable startups.
“What we are seeing from this first cohort is exactly what we set out to create: founders who are not just building products, but building businesses that can scale and create lasting impact,” the founder of Evon Labs, Ms Isioma Udeozo, said of the unveiling of HealthX Catalyst.
The partners of the programme are the United Nations Development Programme (UNDP), Odua Investment Company Limited (OICL), Washington University of St Louis, Missouri, Lagos State Employment Trust Fund (LSETF), and Brooks Insights.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn